Tax-driven sale as Metagenomi (MGX) director Irish reports 3,737 shares sold
Rhea-AI Filing Summary
Metagenomi Therapeutics director and officer Jian Irish reported an automatic share sale tied to tax withholding. On June 5, 2026, 3,737 shares of Metagenomi Therapeutics, Inc. common stock were sold at $1.299 per share to satisfy tax obligations arising from the vesting of restricted stock units granted on April 1, 2024 and April 1, 2025. The filing states this was not a voluntary trade. After the sale, she holds 377,533 shares of common stock directly, and additional shares are held indirectly through family trusts for which she reports but disclaims full beneficial ownership. A footnote also notes that her holdings include 1,500 shares acquired under the company’s employee stock purchase plan on May 29, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,737 | $1.299 | $5K |
| holding | Common Stock | -- | -- | -- |
| holding | Common stock | -- | -- | -- |
Footnotes (1)
- These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person. Includes 1,500 shares acquired under the Company's employee stock purchase plan ("ESPP") on May 29, 2026. Shares held by the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Shares held by the Jian Irish 2023 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.